- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Disease and Diabetes
The Practical Cardiology™ Heart Disease and Diabetes clinical resource center offers readers the latest in the field of diabetes and cardiovascular disease. With the field of cardiometabolic health becoming a focal point in the fight against cardiovascular disease, this page will host content related to the latest FDA approvals, studies, guideline update, and clinical perspectives from advisory board members.
Mediterranean Diet Linked to Reduce Risk of Adverse Pregnancy Outcomes in Nulliparous Women
December 23, 2022
Data from the nuMoM2b study suggests greater adherence to a Mediterranean diet was associated with reductions of 37%, 28%, and 21% in odds of gestational diabetes, preeclampsia, and any adverse pregnancy outcome, respectively, among a cohort of more than 7000 nulliparous women.
Parkinson Disease Treatment, Bromocriptine, Could Reduce Arterial Stiffness, Blood Pressure in Pediatric T1D
December 06, 2022
Data from the BCQR-T1D study, which was funded by the National Institutes of Health, suggest use of the dopamine receptor agonist bromocriptine was associated with improved blood pressure and arterial stiffness after 4 weeks of treatment in youth with type 1 diabetes.
Empagliflozin Did Not Change Left Ventricular Structure, Function in People Without Diabetes
November 06, 2022
Over a six-month period, SGLT2 inhibition with empagliflozin did not change left ventricular structure or function compared with placebo in people without diabetes or significant heart failure.
Top New Trial Data at ESC Congress 2022
September 03, 2022
Although the European Society of Cardiology (ESC) Congress 2022 may be over, our editorial team is recapping the most popular new trial data from the ESC’s first in-person conference since 2019. The top 5 trials, which were chosen based on total views per article, includes DELIVER, TIME, AXIOMATIC-SSP, FIDELITY, and DANCAVAS.
In Patients with Cancer and Diabetes, SGLT2 Inhibitors Could Provide Cardioprotection Against Anthracyclines
August 24, 2022
An analysis of patients treated in the Massachusetts General Brigham hospital system provides into the potential cardioprotective benefits of SGLT2 inhibitor use among patients with diabetes and cancer receiving treatment with anthracyclines.
Study Warns of Significant Increases in Diabetes and Cardiovascular Disease by 2060
August 01, 2022
Using data from the 2020 US Census report and recent NHANES survey data, investigators from Massachusetts General Hospital detail expected increases in the prevalence of cardiovascular risk factors and cardiovascular disease among the US population by 2060.
Dapagliflozin's Cardiorenal Benefits Consistent in T2D, Regardless of Background CV Medication Use
July 20, 2022
A secondary analysis of the DECLARE-TIMI 58 trial details the cardiorenal protective benefits of dapagliflozin across subgroups of patients defined by use of background cardiovascular medication use.
Medicare Advantage Beneficiaries Less Likely to Receive GLP-1 RA and SGLT2 Inhibitor Prescriptions
July 14, 2022
A comparison of data from more than 340,000 Medicare beneficiaries with diabetes provides insight into the real-world differences in the management of these patients, including disparities in the prescription of GLP-1 RAs and SGLT2 inhibitors.
Prediabetes Not as Benign as Once Believed, Associated with Increased Risk of Heart Attacks
June 17, 2022
An analysis of the National Inpatient Sample details the statistically significant increases in the risk of experiencing myocardial infarction, PCI, or CABG in patients with prediabetes compared to their normoglycemic counterparts.